# Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Study · id `cardio:ct-nct01344447` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01344447](<https://clinicaltrials.gov/study/NCT01344447>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01344447

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 479 participants.

## Technical summary

Registry record NCT01344447. Allocation not applicable; no masking; primary purpose diagnostic. Start 2011-05-12 (actual); primary completion 2014-05-28 (actual). Results posted on 2015-08-26.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 479 participants (enrolled count; ClinicalTrials.gov record NCT01344447, source copy `cardio:ctgov-nct01344447-2019-01-04`, retrieved 2026-10-26)
- Started: 2011-05-12 (actual) (ClinicalTrials.gov record NCT01344447, source copy `cardio:ctgov-nct01344447-2019-01-04`, retrieved 2026-10-26)
- Primary completion: 2014-05-28 (actual) (ClinicalTrials.gov record NCT01344447, source copy `cardio:ctgov-nct01344447-2019-01-04`, retrieved 2026-10-26)
- Completion: 2014-05-28 (actual) (ClinicalTrials.gov record NCT01344447, source copy `cardio:ctgov-nct01344447-2019-01-04`, retrieved 2026-10-26)
- Results first posted: 2015-08-26 (ClinicalTrials.gov record NCT01344447, source copy `cardio:ctgov-nct01344447-2019-01-04`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; China; Czechia; France; Germany; Italy; Poland; South Korea; Sweden; Switzerland; Türkiye (ClinicalTrials.gov record NCT01344447, source copy `cardio:ctgov-nct01344447-2019-01-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01344447-2019-01-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Gadobutrol Enhanced MRA of the Supra-aortic Vessels
- Acronym: GEMSAV
- Condition: Carotid Stenosis
- Intervention (Drug): Gadobutrol (Gadovist, BAY86-4875)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Carotid artery stenosis (`cardio:carotid-stenosis`)
- Registry condition terms include this condition: Transient ischemic attack (mini-stroke) (`cardio:transient-ischemic-attack`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: aab93a5679c2f11f6e43a002d81fc599c5192795b0e53727d014ea6b03467fb7
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
